Jim Simons Ambrx Biopharma Inc. Transaction History

Renaissance Technologies LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.41 - $4.54 $12,915 - $143,010	-31,500 Reduced 49.22%	32,500 $74,000
Q3 2022 Nov 14, 2022	BUY	$1.06 - $2.96 $56,180 - $156,880	53,000 Added 481.82%	64,000 $69,000
Q2 2022 Aug 12, 2022	SELL	$2.53 - $4.35 $29,347 - $50,459	-11,600 Reduced 51.33%	11,000 $29,000
Q1 2022 May 13, 2022	BUY	$4.07 - $9.0 $43,956 - $97,200	10,800 Added 91.53%	22,600 $93,000
Q4 2021 Feb 11, 2022	BUY	$8.11 - $13.91 $95,698 - $164,138	11,800 New	11,800 $107,000

31.2K

Ticker AMAM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,618,400
Market Cap $1.08B
Description
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gas...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.